IGM Biosciences, Inc. (IGMS) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lexicon Pharmaceuticals, Inc.

IGM Biosciences, Inc.

Ovid Therapeutics, Inc.

Vanda Pharmaceuticals, Inc.

AC Immune SA

Compass Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

Inozyme Pharma, Inc.

Atea Pharmaceuticals, Inc.

Third Harmonic Bio, Inc.

Acumen Pharmaceuticals, Inc.

Why is IGM Biosciences, Inc. ?

With a growth in Net Sales of 11353.19%, the company declared Outstanding results in Jun 25

OPERATING CASH FLOW(Y) Highest at USD -156.51 MM
NET SALES(HY) Higher at USD 144.12 MM
ROCE(HY) Highest at -47.82%

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to IGM Biosciences, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is IGM Biosciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

IGM Biosciences, Inc.

-86.3%

-0.75

111.78%

S&P 500

13.22%

0.96

19.87%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

170.96%

EBIT Growth (5y)

16.61%

EBIT to Interest (avg)

-189.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-145.10

Sales to Capital Employed (avg)

0.19

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

86.88%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

79.35

EV to EBIT

0.38

EV to EBITDA

0.41

EV to Capital Employed

0.46

EV to Sales

-24.52

PEG Ratio

Dividend Yield

ROCE (Latest)

118.81%

ROE (Latest)

-16082.30%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

41What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -156.51 MM

NET SALES(HY)

Higher at USD 144.12 MM

ROCE(HY)

Highest at -47.82%

OPERATING PROFIT(Q)

Highest at USD 130.73 MM

PRE-TAX PROFIT(Q)

Highest at USD 131.61 MM

NET PROFIT(Q)

Highest at USD 131.61 MM

RAW MATERIAL COST(Y)

Fallen by -219.62% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 580.2%

EPS(Q)

Highest at USD 1.58

-2What is not working for the Company

CASH AND EQV(HY)

Lowest at USD 256.42 MM

DEBT-EQUITY RATIO (HY)

Highest at -103.34 %

Here's what is working for IGM Biosciences, Inc.

Net Sales

At USD 144.12 MM has Grown at 8,130.84%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit

At USD 131.61 MM has Grown at 374.75%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 131.61 MM has Grown at 374.75%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Cash Flow

Highest at USD -156.51 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit

Highest at USD 130.73 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD 131.61 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD 131.61 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

Higher at USD 144.12 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

EPS

Highest at USD 1.58

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debtors Turnover Ratio

Highest at 580.2%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -219.62% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for IGM Biosciences, Inc.

Cash and Eqv

Lowest at USD 256.42 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -103.34 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Non Operating Income

Highest at USD 0.01 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income